Literature DB >> 22785237

Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people.

Yasushi Kirino1, Masako Sei, Kazuyoshi Kawazoe, Kazuo Minakuchi, Youichi Sato.   

Abstract

We previously found that plasma dipeptidyl peptidase 4 (DPP4) activity was associated with the development of obesity, type 2 diabetes, and type 1 diabetes using animal models. In this study, we investigated whether DPP4 activity is correlated with the clinical parameters of obesity and/or diabetes in healthy young subjects. Body mass index (BMI), plasma DPP4 activity, total cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, fasting blood glucose, adiponectin concentration, and body fat were measured in 165 subjects (110 males and 55 females, age 23.2 ± 2.4 years). In correlation analyses, DPP4 activity displayed strong positive correlations with BMI (p = 5.5 × 10(-5)) and total cholesterol (p = 0.0014), and a negative correlation with the plasma adiponectin concentration (p = 0.013), but not fasting blood glucose. Our findings suggest that plasma DPP4 activity is correlated with the clinical parameters of obesity rather than diabetes in young people.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785237     DOI: 10.1507/endocrj.ej12-0158

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  30 in total

Review 1.  Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.

Authors:  Salvatore Carbone; Dave L Dixon; Leo F Buckley; Antonio Abbate
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

2.  Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress.

Authors:  T Zheng; T Chen; Y Liu; Y Gao; H Tian
Journal:  J Hum Hypertens       Date:  2014-11-20       Impact factor: 3.012

3.  MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.

Authors:  Tatsuya Ohyama; Ken Sato; Yuichi Yamazaki; Hiroaki Hashizume; Norio Horiguchi; Satoru Kakizaki; Masatomo Mori; Motoyasu Kusano; Masanobu Yamada
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

4.  Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.

Authors:  Devram S Ghorpade; Lale Ozcan; Ze Zheng; Sarah M Nicoloro; Yuefei Shen; Emily Chen; Matthias Blüher; Michael P Czech; Ira Tabas
Journal:  Nature       Date:  2018-03-21       Impact factor: 49.962

5.  Targeting Soluble DPP-4 for Insulin Resistance: Origin Matters.

Authors:  Lale Ozcan; Devram S Ghorpade; Ira Tabas
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

Review 6.  The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.

Authors:  L Pala; C M Rotella
Journal:  J Diabetes Res       Date:  2013-06-18       Impact factor: 4.011

7.  Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.

Authors:  Nobuya Inagaki; Wenying Yang; Hirotaka Watada; Linong Ji; Sven Schnaidt; Egon Pfarr; Tomoo Okamura; Odd Erik Johansen; Jyothis T George; Maximilian von Eynatten; Julio Rosenstock; Vlado Perkovic; Christoph Wanner; Mark E Cooper; John H Alexander; Issei Komuro; Masaomi Nangaku
Journal:  Diabetol Int       Date:  2019-10-22

8.  Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.

Authors:  Shusuke Yagi; Ken-Ichi Aihara; Masashi Akaike; Daiju Fukuda; Hotimah Masdan Salim; Masayoshi Ishida; Tomomi Matsuura; Takayuki Ise; Koji Yamaguchi; Takashi Iwase; Hirotsugu Yamada; Takeshi Soeki; Tetsuzo Wakatsuki; Michio Shimabukuro; Toshio Matsumoto; Masataka Sata
Journal:  Diabetes Metab J       Date:  2015-07-21       Impact factor: 5.376

Review 9.  Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2015-09-29       Impact factor: 9.951

10.  Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in Chinese over 4 years: result from the China National Diabetes and Metabolic Disorders Study.

Authors:  Fan Yang; Tianpeng Zheng; Yun Gao; Attit Baskota; Tao Chen; Xingwu Ran; Haoming Tian
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.